Skip to content

Study · Randomized controlled trial · n = 48 · 2026

7 results

Abaloparatide and pelvic fracture healing: a phase 2 randomized placebo-controlled trial.

Nieves JW, Cosman F, McMahon D, Berman H, Bartolotta RJ, Kazam JJ, Hentschel I, Egol K, Forsh D, Zhu YS, Yoo JE, Lane J

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA20 Aug 2026

PMID42618812 (opens in a new tab)DOI10.1007/s00198-026-08176-2 (opens in a new tab)PepBankPUB-42618812
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic fracture, abaloparatide did not significantly change CT bridging score distribution versus placebo at 3 months.

    In plain wordsIn patients with pelvic fracture, abaloparatide did not significantly change CT healing scores versus placebo at 3 months.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changePatient CT bridging score distribution
    Study

    n = 48

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CT images at 3 months showed no significant difference in bridging score distribution (indicator of healing) in patients with ABL vs. PBO (p = 0.15) after adjusting for age, sacral fracture, displacement, or compliance.
    1 context sentence
    Summary · context
    Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO. The primary endpoint, fracture healing at 3 months, was assessed by two radiologists using a 5-point scale for cortical bridging from CT images comparing groups b…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic fracture, 39% healed with abaloparatide versus 64% with placebo, with uncertainty including no difference.

    In plain wordsIn patients with pelvic fracture, 39% healed with abaloparatide versus 64% with placebo, without a significant difference.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changePatients healed
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Patients healed
    39%
    Abaloparatide
    Patients healed
    64%
    Placebo
    Relative risk
    0.61 ratio
    Abaloparatide versus placebo
    Lower confidence bound
    0.33 ratio
    95% CI
    Upper confidence bound
    1.12 ratio
    95% CI

    Source sentences

    Summary
    When patients were stratified as healed or not healed, 39% were healed with ABL and 64% healed with PBO (RR 0.61; 95% CI 0.33, 1.12).
    1 context sentence
    Summary · context
    Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic fracture, change in pain score did not differ between abaloparatide and placebo.

    In plain wordsIn patients with pelvic fracture, pain changes did not differ between abaloparatide and placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeChange in NRS pain
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Pain · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but there were no further group differences in change in pain score
    1 context sentence
    Summary · context
    Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic fracture, SPPB scores improved over time in both abaloparatide and placebo groups without group differences.

    In plain wordsIn patients with pelvic fracture, physical performance scores improved in both abaloparatide and placebo groups without group differences.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSPPB score
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SPPB and TUG scores improved over time in both groups without group differences.
    1 context sentence
    Summary · context
    Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic fracture, TUG scores improved over time in both abaloparatide and placebo groups without group differences.

    In plain wordsIn patients with pelvic fracture, TUG mobility scores improved in both abaloparatide and placebo groups without group differences.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTUG score
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    SPPB and TUG scores improved over time in both groups without group differences.
    1 context sentence
    Summary · context
    Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic fracture, individual fracture bridging scores were similar with abaloparatide and placebo.

    In plain wordsIn patients with pelvic fracture, healing scores for individual fractures were similar with abaloparatide and placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeIndividual fracture bridging scores
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    When evaluating individual fractures (n = 81), similar bridging scores were seen with ABL and PBO (p = 0.13).
    1 context sentence
    Summary · context
    Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with pelvic fracture, 47% of individual fractures healed with abaloparatide versus 53% with placebo, without significant difference.

    In plain wordsIn patients with pelvic fracture, 47% of individual fractures healed with abaloparatide versus 53% with placebo, without significant difference.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeIndividual fractures healed
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Fractures healed
    47%
    Abaloparatide
    Fractures healed
    53%
    Placebo
    Relative risk
    0.88 ratio
    Abaloparatide versus placebo
    Lower confidence bound
    0.55 ratio
    95% CI
    Upper confidence bound
    1.4 ratio
    95% CI

    Source sentences

    Summary
    When looking at the 81 individual fractures, 47% were healed with ABL and 53% healed with PBO (RR = 0.88; 95% CI 0.55, 1.40).
    1 context sentence
    Summary · context
    Postmenopausal women and men ≥ 50 years old, enrolled within 4 weeks of pelvic fracture (n = 48), were randomized to blinded ABL vs. PBO.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04249232

Abaloparatide and Pelvic Fracture Healing

Hospital for Special Surgery, New Yorkn = 4817 Sept 2020 to 25 Apr 2024

Fracture of Pelvis (Disorder)

Trial pageClinicalTrials.govUpdated 14 Jun 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.